Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bi-4SCAR-CD19/22 T Cells in B Cell Malignancies
NCT05432882Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR19/22 T cells in B-cell malignancy, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
4SCAR19/22 T cells
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT05432882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432882.